Dr. Pinter-Brown on CTCL Combination Therapies

Lauren Pinter-Brown, MD
Published: Wednesday, Mar 13, 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma (CTCL).

Combination therapies in CTCL have not been studied a great deal. There is a desire for many practicing physicians to "layer" treatments that only garner some response to prevent the disease from breaking loose, Pinter-Brown says. As a result, patients are often treated with combinations that have not been studied. There are some combination therapies that have been studied: retinoids with light, interferon with light, photopheresis with interferon, and photopheresis with retinioids.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma (CTCL).

Combination therapies in CTCL have not been studied a great deal. There is a desire for many practicing physicians to "layer" treatments that only garner some response to prevent the disease from breaking loose, Pinter-Brown says. As a result, patients are often treated with combinations that have not been studied. There are some combination therapies that have been studied: retinoids with light, interferon with light, photopheresis with interferon, and photopheresis with retinioids.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x